Novartis has completed the spin-off of Sandoz‘s generics and biosimilars business, with the result that Sandoz Group debuted as an independent, publicly traded company. Sandoz shares were successfully listed on the Swiss stock exchange,
Tags :Oliver M. Brupbacher
Bär & Karrer incorporates new professionals to the firm. Claudia Götz Staehelin (pictured left) and Oliver M. Brupbacher (pictured right) will join the firm as partners to reinforce the capabilities in the Basel
Kellerhals Carrard represented Moderna biotechnology company as it was heard as a third party in the inspection of the Control Committee of the National Council (CC-N) that was launched in May 2020 regarding the handling of
Kellerhals Carrard, under the responsibility of partners Claudia Götz Staehelin (pictured), Oliver M. Brupbacher and Nicolas Mosimann, advised Moderna on legal and regulatory aspects related to the establishment of its supply chain for its
